Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.37 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7379778 | 0.93 | FAAH (0.59) | FAAHMEN1MAPK1KMT2APLA2G10 | |
| SCHEMBL7291321 | 0.82 | FAAH (0.47) | FAAHMEN1MAPK1KMT2APLA2G10 | |
| SCHEMBL11136853 | 0.82 | PSMB5 (0.41) | MEN1KMT2APLA2G10PSMB5 | |
| SCHEMBL7377102 | 0.78 | PSMB5 (0.41) | PSMB5 | |
| SCHEMBL20560494 | 0.77 | CTSC (0.43) | MEN1KMT2APSMB5 | |
| SCHEMBL6315286 | 0.77 | CTSC (0.43) | MEN1KMT2APSMB5 | |
| SCHEMBL10783264 | 0.76 | MEN1 (0.58) | FAAHMEN1MAPK1KMT2ADNM1 | |
| SCHEMBL21724578 | 0.76 | FAAH (0.53) | FAAHMEN1MAPK1KMT2APLA2G10 | |
| SCHEMBL21724158 | 0.75 | FAAH (0.56) | FAAHMEN1MAPK1KMT2APLA2G10 | |
| SCHEMBL21724576 | 0.75 | FAAH (0.56) | FAAHMEN1MAPK1KMT2APLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MCKEARN JOHN P (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MMP3, MMP10, MMP25 | FAAH 3638/4885MEN1 1012/4885MAPK1 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.